A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.

Abstract

It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.

• Authors: Y Satoh, K Nakano, H Yoshinari, S Nakayamada, S Iwata, S Kubo, I Miyagawa, M Yoshikawa, Y Miyazaki, K Saito, Y Tanaka
• Journal: Lupus (Lupus) Vol. 27 Issue 7 Pg. 1202-1206 (Jun 2018) ISSN: 1477-0962 [Electronic] England
• PMID: 29523055 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• IL17A protein, human
• Interleukin-17
• secukinumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Female
• Humans
• Interleukin-17 (antagonists & inhibitors, blood)
• Lupus Nephritis (complications)
• Middle Aged
• Psoriasis (drug therapy)